Predicting Optimal Dihydroartemisinin-Piperaquine Regimens to Prevent Malaria During Pregnancy for Human Immunodeficiency Virus-Infected Women Receiving Efavirenz
2018
Аутори
Wallender, ErikaVučićević, Katarina
Jagannathan, Prasanna
Huang, Liusheng
Natureeba, Paul
Kakuru, Abel
Muhindo, Mary
Nakalembe, Mirium
Havlir, Diane
Kamya, Moses
Aweeka, Francesca
Dorsey, Grant
Rosenthal, Philip J.
Savić, Radojka M.
Чланак у часопису (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт
Background. A monthly treatment course of dihydroartemisinin-piperaquine (DHA-PQ) effectively prevents malaria during pregnancy. However, a drug-drug interaction pharmacokinetic (PK) study found that pregnant human immunodeficiency virus (HIV)-infected women receiving efavirenz-based antiretroviral therapy (ART) had markedly reduced piperaquine (PQ) exposure. This suggests the need for alternative DHA-PQ chemoprevention regimens in this population. Methods. Eighty-three HIV-infected pregnant women who received monthly DHA-PQ and efavirenz contributed longitudinal PK and corrected QT interval (QTc) (n = 25) data. Population PK and PK-QTc models for PQ were developed to consider the benefits (protective PQ coverage) and risks (QTc prolongation) of alternative DHA-PQ chemoprevention regimens. Protective PQ coverage was defined as maintaining a concentration > 10 ng/mL for > 95% of the chemoprevention period. Results. PQ clearance was 4540 L/day. With monthly DHA-PQ (2880 mg PQ), lt 1% o...f women achieved defined protective PQ coverage. Weekly (960 mg PQ) or low-dose daily (320 or 160 mg PQ) regimens achieved protective PQ coverage for 34% and > 96% of women, respectively. All regimens were safe, with lt = 2% of women predicted to have >= 30 msec QTc increase. Conclusions. For HIV-infected pregnant women receiving efavirenz, low daily DHA-PQ dosing was predicted to improve protection against parasitemia and reduce risk of toxicity compared to monthly dosing.
Кључне речи:
intermittent preventive treatment during pregnancy / dihydroartemisinin-piperaquine / HIV infection / drug-drug interactionИзвор:
Journal of Infectious Diseases, 2018, 217, 6, 964-972Издавач:
- Oxford Univ Press Inc, Cary
Финансирање / пројекти:
- National Natural Science Foundation of China - 31372466
DOI: 10.1093/infdis/jix660
ISSN: 0022-1899
PubMed: 29272443
WoS: 000427131300015
Scopus: 2-s2.0-85042947997
Институција/група
PharmacyTY - JOUR AU - Wallender, Erika AU - Vučićević, Katarina AU - Jagannathan, Prasanna AU - Huang, Liusheng AU - Natureeba, Paul AU - Kakuru, Abel AU - Muhindo, Mary AU - Nakalembe, Mirium AU - Havlir, Diane AU - Kamya, Moses AU - Aweeka, Francesca AU - Dorsey, Grant AU - Rosenthal, Philip J. AU - Savić, Radojka M. PY - 2018 UR - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3177 AB - Background. A monthly treatment course of dihydroartemisinin-piperaquine (DHA-PQ) effectively prevents malaria during pregnancy. However, a drug-drug interaction pharmacokinetic (PK) study found that pregnant human immunodeficiency virus (HIV)-infected women receiving efavirenz-based antiretroviral therapy (ART) had markedly reduced piperaquine (PQ) exposure. This suggests the need for alternative DHA-PQ chemoprevention regimens in this population. Methods. Eighty-three HIV-infected pregnant women who received monthly DHA-PQ and efavirenz contributed longitudinal PK and corrected QT interval (QTc) (n = 25) data. Population PK and PK-QTc models for PQ were developed to consider the benefits (protective PQ coverage) and risks (QTc prolongation) of alternative DHA-PQ chemoprevention regimens. Protective PQ coverage was defined as maintaining a concentration > 10 ng/mL for > 95% of the chemoprevention period. Results. PQ clearance was 4540 L/day. With monthly DHA-PQ (2880 mg PQ), lt 1% of women achieved defined protective PQ coverage. Weekly (960 mg PQ) or low-dose daily (320 or 160 mg PQ) regimens achieved protective PQ coverage for 34% and > 96% of women, respectively. All regimens were safe, with lt = 2% of women predicted to have >= 30 msec QTc increase. Conclusions. For HIV-infected pregnant women receiving efavirenz, low daily DHA-PQ dosing was predicted to improve protection against parasitemia and reduce risk of toxicity compared to monthly dosing. PB - Oxford Univ Press Inc, Cary T2 - Journal of Infectious Diseases T1 - Predicting Optimal Dihydroartemisinin-Piperaquine Regimens to Prevent Malaria During Pregnancy for Human Immunodeficiency Virus-Infected Women Receiving Efavirenz VL - 217 IS - 6 SP - 964 EP - 972 DO - 10.1093/infdis/jix660 ER -
@article{ author = "Wallender, Erika and Vučićević, Katarina and Jagannathan, Prasanna and Huang, Liusheng and Natureeba, Paul and Kakuru, Abel and Muhindo, Mary and Nakalembe, Mirium and Havlir, Diane and Kamya, Moses and Aweeka, Francesca and Dorsey, Grant and Rosenthal, Philip J. and Savić, Radojka M.", year = "2018", abstract = "Background. A monthly treatment course of dihydroartemisinin-piperaquine (DHA-PQ) effectively prevents malaria during pregnancy. However, a drug-drug interaction pharmacokinetic (PK) study found that pregnant human immunodeficiency virus (HIV)-infected women receiving efavirenz-based antiretroviral therapy (ART) had markedly reduced piperaquine (PQ) exposure. This suggests the need for alternative DHA-PQ chemoprevention regimens in this population. Methods. Eighty-three HIV-infected pregnant women who received monthly DHA-PQ and efavirenz contributed longitudinal PK and corrected QT interval (QTc) (n = 25) data. Population PK and PK-QTc models for PQ were developed to consider the benefits (protective PQ coverage) and risks (QTc prolongation) of alternative DHA-PQ chemoprevention regimens. Protective PQ coverage was defined as maintaining a concentration > 10 ng/mL for > 95% of the chemoprevention period. Results. PQ clearance was 4540 L/day. With monthly DHA-PQ (2880 mg PQ), lt 1% of women achieved defined protective PQ coverage. Weekly (960 mg PQ) or low-dose daily (320 or 160 mg PQ) regimens achieved protective PQ coverage for 34% and > 96% of women, respectively. All regimens were safe, with lt = 2% of women predicted to have >= 30 msec QTc increase. Conclusions. For HIV-infected pregnant women receiving efavirenz, low daily DHA-PQ dosing was predicted to improve protection against parasitemia and reduce risk of toxicity compared to monthly dosing.", publisher = "Oxford Univ Press Inc, Cary", journal = "Journal of Infectious Diseases", title = "Predicting Optimal Dihydroartemisinin-Piperaquine Regimens to Prevent Malaria During Pregnancy for Human Immunodeficiency Virus-Infected Women Receiving Efavirenz", volume = "217", number = "6", pages = "964-972", doi = "10.1093/infdis/jix660" }
Wallender, E., Vučićević, K., Jagannathan, P., Huang, L., Natureeba, P., Kakuru, A., Muhindo, M., Nakalembe, M., Havlir, D., Kamya, M., Aweeka, F., Dorsey, G., Rosenthal, P. J.,& Savić, R. M.. (2018). Predicting Optimal Dihydroartemisinin-Piperaquine Regimens to Prevent Malaria During Pregnancy for Human Immunodeficiency Virus-Infected Women Receiving Efavirenz. in Journal of Infectious Diseases Oxford Univ Press Inc, Cary., 217(6), 964-972. https://doi.org/10.1093/infdis/jix660
Wallender E, Vučićević K, Jagannathan P, Huang L, Natureeba P, Kakuru A, Muhindo M, Nakalembe M, Havlir D, Kamya M, Aweeka F, Dorsey G, Rosenthal PJ, Savić RM. Predicting Optimal Dihydroartemisinin-Piperaquine Regimens to Prevent Malaria During Pregnancy for Human Immunodeficiency Virus-Infected Women Receiving Efavirenz. in Journal of Infectious Diseases. 2018;217(6):964-972. doi:10.1093/infdis/jix660 .
Wallender, Erika, Vučićević, Katarina, Jagannathan, Prasanna, Huang, Liusheng, Natureeba, Paul, Kakuru, Abel, Muhindo, Mary, Nakalembe, Mirium, Havlir, Diane, Kamya, Moses, Aweeka, Francesca, Dorsey, Grant, Rosenthal, Philip J., Savić, Radojka M., "Predicting Optimal Dihydroartemisinin-Piperaquine Regimens to Prevent Malaria During Pregnancy for Human Immunodeficiency Virus-Infected Women Receiving Efavirenz" in Journal of Infectious Diseases, 217, no. 6 (2018):964-972, https://doi.org/10.1093/infdis/jix660 . .